开云app官网登录入口网页版-官方正版

#抗血管#

45篇内容 | 1673人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1932990, encodeId=d16d1932990a9, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=肺癌 | EGFR突变，奥希替尼联合抗血管治疗无优势, objectType=article, longId=730863, objectId=42ade3086341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42ade3086341, replyNumber=0, likeNumber=88, createdTime=2023-05-27, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42ade3086341, moduleTitle=肺癌 | EGFR突变，奥希替尼联合抗血管治疗无优势, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=42ade3086341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932984, encodeId=ca8c1932984ef, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=抗血管治疗点亮晚期NSCLC一线治疗的新选择, objectType=article, longId=220753, objectId=fdb1220e5399, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdb1220e5399, replyNumber=0, likeNumber=85, createdTime=2021-12-20, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdb1220e5399, moduleTitle=抗血管治疗点亮晚期NSCLC一线治疗的新选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fdb1220e5399)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932985, encodeId=8f721932985f4, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=晚期NSCLC抗血管生成治疗进展, objectType=article, longId=220768, objectId=379b220e680e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=379b220e680e, replyNumber=0, likeNumber=82, createdTime=2022-05-30, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=379b220e680e, moduleTitle=晚期NSCLC抗血管生成治疗进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=379b220e680e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932989, encodeId=a4e9193298998, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, objectType=article, longId=295276, objectId=d9be2952e62d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be2952e62d, replyNumber=0, likeNumber=98, createdTime=2023-01-19, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be2952e62d, moduleTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d9be2952e62d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932983, encodeId=ff411932983c3, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, objectType=article, longId=220296, objectId=ddf8220296a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddf8220296a1, replyNumber=0, likeNumber=88, createdTime=2022-07-05, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddf8220296a1, moduleTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ddf8220296a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932982, encodeId=7b9e1932982eb, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）, objectType=article, longId=215743, objectId=7f20215e43ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f20215e43ec, replyNumber=0, likeNumber=138, createdTime=2022-06-07, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f20215e43ec, moduleTitle=Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7f20215e43ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932987, encodeId=561b193298eab, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=翟怡：晚期NSCLC抗血管生成与免疫治疗的共赢合作, objectType=article, longId=221083, objectId=aec522108386, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aec522108386, replyNumber=0, likeNumber=71, createdTime=2022-04-28, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aec522108386, moduleTitle=翟怡：晚期NSCLC抗血管生成与免疫治疗的共赢合作, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aec522108386)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932988, encodeId=8cb71932988cb, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, objectType=article, longId=292663, objectId=79a729266362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79a729266362, replyNumber=0, likeNumber=89, createdTime=2022-05-18, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79a729266362, moduleTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=79a729266362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932986, encodeId=0e7119329864d, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=晚期肺癌免疫联合抗血管生成治疗, objectType=article, longId=220783, objectId=b5b5220e831a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5b5220e831a, replyNumber=0, likeNumber=83, createdTime=2022-05-31, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5b5220e831a, moduleTitle=晚期肺癌免疫联合抗血管生成治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b5b5220e831a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932981, encodeId=8911193298184, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=BJU Int：肾细胞癌中的癌症相关成纤维细胞对预后和抗血管生成疗法的影响研究 , objectType=article, longId=213377, objectId=b6e62133e79c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6e62133e79c, replyNumber=0, likeNumber=0, createdTime=2021-12-15, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6e62133e79c, moduleTitle=BJU Int：肾细胞癌中的癌症相关成纤维细胞对预后和抗血管生成疗法的影响研究 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b6e62133e79c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932980, encodeId=bda419329808c, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=《晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）》正式发布，助力晚期NSCLC临床治疗水平提升, objectType=article, longId=200723, objectId=8637200e2372, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8637200e2372, replyNumber=0, likeNumber=94, createdTime=2021-05-22, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8637200e2372, moduleTitle=《晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）》正式发布，助力晚期NSCLC临床治疗水平提升, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8637200e2372)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932975, encodeId=329219329e5cc, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=妇科肿瘤抗血管内皮生长因子单克隆抗体临床应用指南, objectType=article, longId=188079, objectId=dfe61880e9cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfe61880e9cb, replyNumber=0, likeNumber=92, createdTime=2020-11-29, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfe61880e9cb, moduleTitle=妇科肿瘤抗血管内皮生长因子单克隆抗体临床应用指南, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dfe61880e9cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932979, encodeId=273f19329e94b, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=Clin Cancer Res：伊曲康唑在NSCLC中的浓度依赖性的早期抗血管、抗肿瘤作用, objectType=article, longId=200026, objectId=3a7b200026d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a7b200026d1, replyNumber=0, likeNumber=79, createdTime=2021-03-11, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a7b200026d1, moduleTitle=Clin Cancer Res：伊曲康唑在NSCLC中的浓度依赖性的早期抗血管、抗肿瘤作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3a7b200026d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932976, encodeId=decf19329e601, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, objectType=article, longId=188479, objectId=2f351884e941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f351884e941, replyNumber=0, likeNumber=94, createdTime=2020-11-25, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f351884e941, moduleTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2f351884e941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932977, encodeId=ad6319329e734, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, objectType=article, longId=191912, objectId=afff191912f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afff191912f3, replyNumber=0, likeNumber=83, createdTime=2020-12-12, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afff191912f3, moduleTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=afff191912f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932978, encodeId=781419329e8c7, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, objectType=article, longId=192249, objectId=f473192249cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f473192249cd, replyNumber=0, likeNumber=81, createdTime=2020-06-25, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f473192249cd, moduleTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f473192249cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932966, encodeId=01281932966e3, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=免疫治疗时代，化疗和抗血管生成治疗在肺癌中的地位如何？, objectType=article, longId=175517, objectId=ea451e5517ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea451e5517ba, replyNumber=0, likeNumber=143, createdTime=2020-03-19, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea451e5517ba, moduleTitle=免疫治疗时代，化疗和抗血管生成治疗在肺癌中的地位如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea451e5517ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932974, encodeId=140019329e4ee, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=《妇科肿瘤抗血管生长因子单克隆抗体临床应用指南》重磅发布！, objectType=article, longId=186010, objectId=19e018601096, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e018601096, replyNumber=0, likeNumber=147, createdTime=2020-06-06, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e018601096, moduleTitle=《妇科肿瘤抗血管生长因子单克隆抗体临床应用指南》重磅发布！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19e018601096)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932972, encodeId=832519329e2b8, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=韩小弟教授：抗血管生成药物给胶质母细胞瘤患者带来生存希望, objectType=article, longId=180146, objectId=af1c18014633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af1c18014633, replyNumber=0, likeNumber=123, createdTime=2020-03-10, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af1c18014633, moduleTitle=韩小弟教授：抗血管生成药物给胶质母细胞瘤患者带来生存希望, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=af1c18014633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932973, encodeId=b63e19329e335, content=<a href='/topic/show?id=6b1255e66ba' target=_blank style='color:#2F92EE;'>#抗血管#</a>, objectTitle=肺癌诊疗发展不断突破，抗血管生成联合治疗值得期待, objectType=article, longId=182239, objectId=a7a9182239f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7a9182239f8, replyNumber=0, likeNumber=97, createdTime=2019-12-20, rootId=0, userName=flyingeagle77, userId=9fe6351, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7a9182239f8, moduleTitle=肺癌诊疗发展不断突破，抗血管生成联合治疗值得期待, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a7a9182239f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

抗血管

2020-05-29

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

肺癌 | EGFR突变，奥希替尼联合抗血管治疗无优势

2023-05-27

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

抗血管治疗点亮晚期NSCLC一线治疗的新选择

2021-12-20

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

晚期NSCLC抗血管生成治疗进展

2022-05-30

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效

2023-01-19

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估

2022-07-05

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）

2022-06-07

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

翟怡：晚期NSCLC抗血管生成与免疫治疗的共赢合作

2022-04-28

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR

2022-05-18

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

晚期肺癌免疫联合抗血管生成治疗

2022-05-31

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

BJU Int：肾细胞癌中的癌症相关成纤维细胞对预后和抗血管生成疗法的影响研究

2021-12-15

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

《晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）》正式发布，助力晚期NSCLC临床治疗水平提升

2021-05-22

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

妇科肿瘤抗血管内皮生长因子单克隆抗体临床应用指南

2020-11-29

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

Clin Cancer Res：伊曲康唑在NSCLC中的浓度依赖性的早期抗血管、抗肿瘤作用

2021-03-11

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性

2020-11-25

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准

2020-12-12

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验

2020-06-25

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

免疫治疗时代，化疗和抗血管生成治疗在肺癌中的地位如何？

2020-03-19

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

《妇科肿瘤抗血管生长因子单克隆抗体临床应用指南》重磅发布！

2020-06-06

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

韩小弟教授：抗血管生成药物给胶质母细胞瘤患者带来生存希望

2020-03-10

flyingeagle77 (审核中...)

前往app查看评论内容

#抗血管#

肺癌诊疗发展不断突破，抗血管生成联合治疗值得期待

2019-12-20

科室
- - 订阅+
  - 更多科室
工具
服务